1. Cosmetic surgery national data bank: statistics 2012. Aesthet Surg J 2013;33:S1-21.

2. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: An evidence-based review. Plast Reconstr Surg 2008;121:e413-22.

3. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010;36 Suppl 4:2182-7.

4. Ipsen Biopharmaceuticals, Medicis Aesthetics. Medication Guide Dysport (dis-port) (abobotulinumtoxinA) Injection. 2012. Availabe from: [Last accessed on 2014 Jul 10].

5. Merz Pharmaceuticals, Merz Aesthetics. Medication Guide Xeomin (zeo-min) (incobotulinumtoxinA) for Injection, for Intramuscular Use. 2011. Available from: EM00674-XEOMIN-Medication-Guide.pdf. [Last accessed on 2014 Jul 10].

6. Matarasso A, Shafer D. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide. Aesthet Surg J 2009;29:S72-9.

7. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 2010;11:183-99.

8. Michaels BM, Csank GA, Ryb GE, Eko FN, Rubin A. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthet Surg J 2012;32:96-102.

9. Freeman SR, Cohen JL. New neurotoxins on the horizon. Aesthet Surg J 2008;28:325-30.

10. Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, Flynn TC, Carruthers A. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010;36 Suppl 4:2146-54.

11. Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor MS, Sclafani AP, Sykes JM, Waldorf HA. IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing. Aesthet Surg J 2013;33:S18-22.

12. Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg 2008;122:1915-25.

13. Kane MA, Brandt F, Rohrich RJ, Narins RS, Monheit GD, Huber MB, Reloxin Investigational Group. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009;124:1619-29.

14. Baumann L, Brandt FS, Kane MA, Donofrio LM. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009;29:S57-65.

15. Rubin M, Dover J, Maas C, Nestor M. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009;29:S50-6.

16. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, Botox Glabellar Lines II Study Group. II. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089-98.

17. Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 2005;31:1651-4.

18. Prager W. Differential characteristics of incobotulinumtoxin A and its use in the management of glabellar frown lines. Clin Pharmacol 2013;5:39-52.

19. Carruthers A, Carruthers J. Commentary: long-term treatment of glabellar rhytides using onabotulinumtoxina. Dermatol Surg 2011;37:929-30.

20. Prager W, Huber-Vorländer J, Taufig AZ, Imhof M, Kühne U, Weissberg R, Kuhr LP, Rippmann V, Philipp-Dormston WG, Proebstle TM, Roth C, Kerscher M, Ulmann C, Pavicic T. Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol 2012;5:53-8.

21. Moy R, Maas C, Monheit G, Huber MB, Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009;11:77-83.

22. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009;35:1893-901.

Plastic and Aesthetic Research
ISSN 2349-6150 (Online)   2347-9264 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: